Trends in surveillance testing after treatment for colorectal cancer remained relatively stable recently, and patients who overutilized surveillance measures had quicker recurrence detection but ...

NEW YORK (Reuters Health) - The results of new research indicate that many older patients who survive colorectal cancer do not attend the guideline-recommended follow-up office visits or undergo ...

Retrospective health care claims database analysis of direct medical costs of newly diagnosed patients (pts) with hepatocellular carcinoma (HCC) in the United States. Background: Relapse after ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Palmetto GBA, a Medicare administrative contractor that administers ...

Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors. The latest market report published by Credence Research, Inc. “Global Carcinoembryonic Antigen (CEA) Market - ...

A new secondary analysis of a randomized clinical trial examined 10-year mortality data from 2456 patients diagnosed with stage II or III colorectal cancer. Improved treatments for metastatic disease ...

Blood test for minimal residual disease (MRD) now covered to monitor for disease recurrence after curative intent treatment Tissue-free approach addresses need for cancer patients who have no tissue ...